Base de datos : IBECS
Búsqueda : "1699-048X" [ISSN]
Referencias encontradas : 2068 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 207 va a la página                         

  1 / 2068 IBECS  
              next record last record
selecciona
para imprimir
Texto Completo
Id: ET1-2946 IBECS-Express
Autor: Bayo, J; Molina, R; Pérez, J; Pérez-Ruíz, E; Aparicio, J; Beato, C; Berros, JP; Bolaños, M; Graña, B; Santaballa, A.
Título: SEOM clinical guidelines to primary prevention of cancer (2018)
Fuente: Clin. transl. oncol. (Print);21(1):106-113, ene. 2019. tab.
Idioma: en.
doi: 10.1007/s12094-018-02016-4.
Resumen: Cancer is the leading social and healthcare problem of the twenty-first century. The aim of primary prevention is to decrease the incidence of cancer by avoiding the known causes and risk factors. Nevertheless, it has been estimated that cancer diagnoses could be halved through primary prevention measures. A comprehensive review of the scientific evidence regarding the main carcinogens and risk factors and primary prevention recommendations have been put forth based on this evidence. The GRADE scale has been used to classify the grade of evidence. We present the scientific evidence and recommendations for primary prevention of the major modifiable risk factors: smoking, alcohol, diet, obesity, physical activity, occupational and environmental factors, ultraviolet radiation, infections, and socioeconomic factors. Primary prevention is a simple, effective means to lower the incidence of cancer. Preventive measures must be circulated in the fight against cancer

No disponible
Responsable: BNCS


  2 / 2068 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Id: ET1-2945 IBECS-Express
Autor: Virizuela, JA; García, AM; Peñas, R de las; Santaballa, A; Andrés, R; Beato, C; Cruz, S de la; Gavilá, J; González-Santiago, S; Fernández, TL.
Título: SEOM clinical guidelines on cardiovascular toxicity (2018)
Fuente: Clin. transl. oncol. (Print);21(1):94-105, ene. 2019. tab, graf.
Idioma: en.
doi: 10.1007/s12094-018-02017-3.
Resumen: One of the most common side effects of cancer treatment is cardiovascular disease, which substantially impacts long-term survivor's prognosis. Cardiotoxicity can be related with either a direct side effect of antitumor therapies or an accelerated development of cardiovascular diseases in the presence of preexisting risk factors. Even though it is widely recognized as an alarming clinical problem, scientific evidence is scarce in the management of these complications in cancer patients. Consequently, current recommendations are based on expert consensus. This Guideline represents SEOM's ongoing commitment to progressing and improving supportive care for cancer patients

No disponible
Responsable: BNCS


  3 / 2068 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Id: ET1-2944 IBECS-Express
Autor: Peñas, R de las; Majem, M; Perez-Altozano, J; Virizuela, JA; Cancer, E; Diz, P; Donnay, O; Hurtado, A; Jimenez-Fonseca, P; Ocon, MJ.
Título: SEOM clinical guidelines on nutrition in cancer patients (2018)
Fuente: Clin. transl. oncol. (Print);21(1):87-93, ene. 2019. tab.
Idioma: en.
doi: 10.1007/s12094-018-02009-3.
Resumen: Nutritional deficiency is a common medical problem that affects 15-40% of cancer patients. It negatively impacts their quality of life and can compromise treatment completion. Oncological therapies, such as surgery, radiation therapy, and drug therapies are improving survival rates. However, all these treatments can play a role in the development of malnutrition and/or metabolic alterations in cancer patients, induced by the tumor or by its treatment. Nutritional assessment of cancer patients is necessary at the time of diagnosis and throughout treatment, so as to detect nutritional deficiencies. The Patient-Generated Subjective Global Assessment method is the most widely used tool that also evaluates nutritional requirements. In this guideline, we will review the indications of nutritional interventions as well as artificial nutrition in general and according to the type of treatment (radiotherapy, surgery, or systemic therapy), or palliative care. Likewise, pharmacological agents and pharmaconutrients will be reviewed in addition to the role of regular physical activity

No disponible
Responsable: BNCS


  4 / 2068 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Id: ET1-2943 IBECS-Express
Autor: Carmona-Bayonas, A; Jimenez-Fonseca, P; Castro, EM de; Mata, E; Biosca, M; Custodio, A; Espinosa, J; Vázquez, EG; Henao, F; Ayala de la Peña, F.
Título: SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)
Fuente: Clin. transl. oncol. (Print);21(1):75-86, ene. 2019. tab, graf.
Idioma: en.
doi: 10.1007/s12094-018-1983-4.
Resumen: Febrile neutropenia (FN) is a common dose-limiting toxicity of chemotherapy, with a profound impact on the evolution of patients with cancer, due to the potential development of serious complications, mortality, delays, and decrease in treatment intensity. This article seeks to present an updated clinical guideline, with recommendations regarding the diagnosis, prevention, and treatment of febrile neutropenia in adults with solid tumors. The aspects covered include how to properly approach the risk of microbial resistances, epidemiological aspects, considerations about the initial empirical approach adapted to the risk, special situations, and prevention of complications. A decision-making algorithm is included for use in the emergency department based on a new, validated tool, the Clinical Index of Stable Febrile Neutropenia, which can be used in patients with solid tumors who appear stable in the initial phase of neutropenic infections, and can help detect those at high risk for complications in whom early discharge must be avoided

No disponible
Responsable: BNCS


  5 / 2068 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Id: ET1-2942 IBECS-Express
Autor: González del Alba, A; Velasco, G De; Lainez, N; Maroto, P; Morales-Barrera, R; Muñoz-Langa, J; Pérez-Valderrama, B; Basterretxea, L; Caballero, C; Vazquez, S.
Título: SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
Fuente: Clin. transl. oncol. (Print);21(1):64-74, ene. 2019. tab.
Idioma: en.
doi: 10.1007/s12094-018-02001-x.
Resumen: The goal of this article is to provide recommendations about the management of muscle-invasive (MIBC) and metastatic bladder cancer. New molecular subtypes of MIBC are associated with specific clinical-pathological characteristics. Radical cystectomy and lymph node dissection are the gold standard for treatment and neoadjuvant chemotherapy with a cisplatin-based combination should be recommended in fit patients. The role of adjuvant chemotherapy in MIBC remains controversial; its use must be considered in patients with high-risk who are able to tolerate a cisplatin-based regimen, and have not received neoadjuvant chemotherapy. Bladder-preserving approaches are reasonable alternatives to cystectomy in selected patients for whom cystectomy is not contemplated either for clinical or personal reasons. Cisplatin-based combination chemotherapy is the standard first-line protocol for metastatic disease. In the case of unfit patients, carboplatin-gemcitabine should be considered the preferred first-line chemotherapy treatment option, while pembrolizumab and atezolizumab can be contemplated for individuals with high PD-L1 expression. In cases of progression after platinum-based therapy, PD-1/PD-L1 inhibitors are standard alternatives. Vinflunine is another option when anti-PD-1/PD-L1 therapy is not possible. There are no data from randomized clinical trials regarding moving on to immuno-oncology agents

No disponible
Responsable: BNCS


  6 / 2068 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Id: ET1-2941 IBECS-Express
Autor: González-Flores, E; Serrano, R; Sevilla, I; Viúdez, A; Barriuso, J; Benavent, M; Capdevila, J; Jimenez-Fonseca, P; López, C; Garcia-Carbonero, R.
Título: SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)
Fuente: Clin. transl. oncol. (Print);21(1):55-63, ene. 2019. tab, graf.
Idioma: en.
doi: 10.1007/s12094-018-1980-7.
Resumen: NENs are a heterogeneous family of tumors of challenging diagnosis and clinical management. Their incidence and prevalence continue to rise across all sites, stages and grades. Although improved diagnostic techniques have led to earlier detection and stage migration, the improved prognosis documented over time for advanced gastrointestinal and pancreatic neuroendocrine tumors also reflect improvements in therapy. The aim of this guideline is to update practical recommendations for the diagnosis and treatment of gastroenteropancreatic and lung NENs. Diagnostic procedures, histological classification and therapeutic options are briefly discussed, including surgery, liver-directed therapy, peptide receptor radionuclide therapy, and systemic hormonal, cytotoxic or targeted therapy, and treatment algorithms are provided

No disponible
Responsable: BNCS


  7 / 2068 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Id: ET1-2940 IBECS-Express
Autor: Gómez-España, MA; Gallego, J; González-Flores, E; Maurel, J; Páez, D; Sastre, J; Aparicio, J; Benavides, M; Feliu, J; Vera, R.
Título: SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
Fuente: Clin. transl. oncol. (Print);21(1):46-54, ene. 2019. tab, graf.
Idioma: en.
doi: 10.1007/s12094-018-02002-w.
Resumen: Colorectal cancer (CRC) is the second cause of cancer death in Spain, the objective of this guide published by the Spanish Society of Medical Oncology is to develop a consensus for the diagnosis and management of metastatic disease. The optimal treatment strategy for patients with metastatic CRC should be discussed in a multidisciplinary expert team to select the most appropriate treatment, and integrate systemic treatment and other options such as surgery and ablative techniques depending on the characteristics of the tumour, the patient and the location of the disease and metastases

No disponible
Responsable: BNCS


  8 / 2068 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Id: ET1-2939 IBECS-Express
Autor: Chacón López-Muñiz, JI; Cruz Merino, L de la; Gavilá Gregori, J; Martínez Dueñas, E; Oliveira, M; Seguí Palmer, MA; Álvarez López, I; Antolin Novoa, S; Bellet Ezquerra, M; López-Tarruella Cobo, S.
Título: SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
Fuente: Clin. transl. oncol. (Print);21(1):31-45, ene. 2019. tab.
Idioma: en.
doi: 10.1007/s12094-018-02010-w.
Resumen: Although the metastasic breast cancer is still an incurable disease, recent advances have increased significantly the time to progression and the overall survival. However, too much information has been produced in the last 2 years, so a well-based guideline is a valuable document in treatment decision making. The SEOM guidelines are intended to make evidence-based recommendations on how to manage patients with advanced and recurrent breast cancer to achieve the best patient outcomes based on a rational use of the currently available therapies. To assign a level of certainty and a grade of recommendation the United States Preventive Services Task Force guidelines methodology was selected as reference

No disponible
Responsable: BNCS


  9 / 2068 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Id: ET1-2938 IBECS-Express
Autor: Ayala de la Peña, F; Andrés, R; Garcia-Sáenz, JA; Manso, L; Margelí, M; Dalmau, E; Pernas, S; Prat, A; Servitja, S; Ciruelos, E.
Título: SEOM clinical guidelines in early stage breast cancer (2018)
Fuente: Clin. transl. oncol. (Print);21(1):18-30, ene. 2019. tab.
Idioma: en.
doi: 10.1007/s12094-018-1973-6.
Resumen: Breast cancer is the most common cancer in women in our country and it is usually diagnosed in the early and potentially curable stages. Nevertheless, around 20-30% of patients will relapse despite appropriate locoregional and systemic therapies. A better knowledge of this disease is improving our ability to select the most appropriate therapy for each patient with a recent diagnosis of an early stage breast cancer, minimizing unnecessary toxicities and improving long-term efficacy

No disponible
Responsable: BNCS


  10 / 2068 IBECS  
              first record previous record
selecciona
para imprimir
Texto Completo
Id: ET1-2937 IBECS-Express
Autor: Majem, M; Juan, O; Insa, A; Reguart, N; Trigo, JM; Carcereny, E; García-Campelo, R; García, Y; Guirado, M; Provencio, M.
Título: SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Fuente: Clin. transl. oncol. (Print);21(1):3-17, ene. 2019. tab, graf.
Idioma: en.
doi: 10.1007/s12094-018-1978-1.
Resumen: Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New treatments similarly mean that we must reconsider what should be done in oligometastatic disease where local treatment attains greater value

No disponible
Responsable: BNCS



página 1 de 207 va a la página                         
   


Refinar la búsqueda
  Base de datos : IBECS Formulario avanzado   
Buscar por : Formulario libre    Formulario básico

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud